MRNA - Moderna, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.70
+0.10 (+0.44%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close22.60
Open22.65
Bid0.00 x 1100
Ask0.00 x 800
Day's Range22.43 - 23.16
52 Week Range13.03 - 29.79
Volume475,913
Avg. Volume947,651
Market Cap7.468B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire4 days ago

    Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of preclinical data in Science Immunology, showing that mRNA encoding a human monoclonal antibody against the chikungunya virus delivered in a proprietary lipid nanoparticle (LNP) can protect from infection by the virus in vivo.

  • Business Wire14 days ago

    Moderna Reports First Quarter 2019 Financial Results and Provides Business Updates

    Rare Diseases: New development candidate announced for glycogen storage disease type 1a , a rare metabolic disorder; Company now has five rare disease programs in its pipeli

  • Business Wire16 days ago

    Moderna to Present at Bank of America Merrill Lynch 2019 Health Care Conference

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tal Zaks, M.D., Ph.D., Chief Medical Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019 at 9:20 a.m. PT (12:20 p.m. ET). A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.

  • Business Wire23 days ago

    Moderna to Present Preclinical Data at 2019 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

    The Company and academic collaborators to share data from seven preclinical studies demonstrating the potential of mRNA-based therapies to treat rare metabolic and genetic disorder

  • Business Wirelast month

    Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its annual Science Day for analysts and investors on Tuesday, May 7, 2019 at 8:00 a.m. ET in Cambridge, MA. Moderna also announced that it will report its first quarter 2019 financial results before the market opens on Wednesday, May 8, 2019 and, subsequently, host a conference call to discuss these results and provide a corporate update. Moderna’s Science Day will feature presentations from Stephen Hoge M.D., president and Melissa Moore Ph.D., chief scientific officer of Moderna’s mRNA Research Platform with a focus on the Company’s newest advances from its commitment to basic and applied sciences.

  • Business Wire2 months ago

    Moderna to Present at 18th Annual Needham Healthcare Conference

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tal Zaks, M.D., Ph.D., Moderna’s Chief Medical Officer, will participate in a fireside chat at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 11:20 a.m. ET. A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.

  • Business Wire3 months ago

    Moderna Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights Recent Pipeline Progress

    Shows Continued Execution Across its Pipeline of Infectious Disease, Immuno-Oncology and Rare Disease Programs

  • Business Wire3 months ago

    Moderna to Present at Upcoming Investor Conferences in March

    A replay of each webcast will be archived on Moderna’s website for 30 days following the presentations. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

  • Business Wire3 months ago

    Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, March 6, 2019 to report its fourth quarter and full year 2018 financial results and provide a corporate update. The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for 30 days following the call. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

  • Business Wire3 months ago

    Phase 1 Data Published in Nature Communications Show Potential of mRNA Encoding VEGF-A as a Regenerative Therapeutic

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of a Phase 1a/b study in Nature Communications showing the potential of mRNA encoding for vascular endothelial growth factor A (VEGF-A) as a regenerative therapeutic. This approach aims to stimulate the growth of new blood vessels, also known as angiogenesis, to improve blood flow in tissues where it is otherwise restricted.

  • Business Wire3 months ago

    Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced topline data from the first planned interim analysis of safety and immunogenicity from its Phase 1 study of mRNA-1653 in healthy adults.

  • Business Wire3 months ago

    Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the dosing of the first subject in a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944 via intravenous infusion in healthy adults. This is the first monoclonal antibody encoded by mRNA to be dosed in a human and the first development candidate from the Company’s systemic therapeutics modalities to start clinical testing.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Moderna

    NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged ...

  • Business Wire4 months ago

    Newly Published Pre-Clinical Data Show Intratumoral Injections of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses in Treated and Distal Tumors

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of pre-clinical data that shows the therapeutic potential of mRNA-2752, an investigational mRNA immuno-oncology therapy that encodes a novel combination of three immunomodulators designed to activate the immune system to recognize and eradicate tumors that are resistant to checkpoint inhibitors. The study, published in the scientific journal Science Translational Medicine, found that the local delivery of mRNA encoding the secreted cytokines IL23 and IL36γ and the membrane-bound T-cell co-stimulator OX40L, induced a broad immune response promoting tumor regression in both injected lesions and distant un-injected tumors in mice.

  • Business Wire4 months ago

    Dr. John Mendlein to Transition to an Advisory Role at Moderna and Join Flagship Pioneering as an Executive Partner

    Moderna, Inc. (MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that John Mendlein, Ph.D., President of Corporate and Product Strategy, will be leaving the Company effective February 1, 2019 to join Flagship Pioneering as an Executive Partner.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: Moderna and Neurocrine Biosciences

    NEW YORK, NY / ACCESSWIRE / January 14, 2019 / U.S. equities posted strong weekly gains, however, stock closed lower for the day on Friday on concerns over an ongoing U.S. government shutdown and worries ...

  • Business Wire4 months ago

    Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives

    Moderna, Inc. (MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced recent updates to several of its immuno-oncology and rare disease programs and outlined its 2019-2020 corporate objectives. Moderna has 21 mRNA development candidates in its pipeline, with 11 programs now in clinical development.

  • Business Wire5 months ago

    Moderna to Provide Business and Pipeline Updates at the 2019 J.P. Morgan Healthcare Conference

    Moderna, Inc. (MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced today that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at this year’s 37th annual J.P. Morgan Healthcare Conference. A live webcast of both the presentation and question and answer session can be accessed on the investors section of Moderna’s website at investors.modernatx.com. A replay of the webcast also will be archived on Moderna’s website for up to 30 days following the presentation.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: Moderna and Altria

    NEW YORK, NY / ACCESSWIRE / December 10, 2018 / Although Moderna sank in its first day of trading, the stock was still the biggest IPO in the biotech arena ever last week. Shares of Altria Group also hit red territory despite announcing it would take a whopping stake in Canadian marijuana company Cronos Group. Moderna, Inc. shares were down a little over 19% on Friday with nearly 13 million shares traded.

  • GlobeNewswire5 months ago

    Nasdaq Welcomes Moderna, Inc. (Nasdaq: MRNA) to The Nasdaq Stock Market

    Moderna, Inc. (MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on the Nasdaq Stock Market. Moderna is a leader in the development of mRNA medicines, a new class of drugs that directs the body’s cells to produce proteins that have the potential to prevent, treat or cure disease. The company has a pipeline of 21 development candidates, including 10 programs currently in clinical trials.

  • Business Wire5 months ago

    Moderna Announces Pricing of Initial Public Offering

    Moderna, Inc. , a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the pricing of its initial public offering of 26,275,993 shares of common stock at a public offering price of $23.00 per share, before underwriting discounts and commissions.